Peyronies Disease Treatment Global Market Report 2026

Peyronie's disease treatment encompasses medical and therapeutic solutions used to address a condition involving the formation of fibrous scar tissue within the penis, which may result in curvature, pain, and functional difficulties. These treatment approaches are intended to minimize plaque development, improve curvature, relieve discomfort, and restore normal function through pharmaceutical therapies, surgical procedures, and non-invasive interventions. They contribute to better patient outcomes through specialized medical care, therapeutic technologies, and clinical treatment strategies.

The primary treatment categories of Peyronie's disease treatment include non-surgical treatments and surgical treatments. Non-surgical treatments consist of therapeutic approaches such as medications, injections, topical therapies, and medical devices that are intended to lessen penile curvature and related symptoms without requiring surgery. These treatment options are delivered through oral, injectable, topical, and device-based or external administration routes and are utilized by end users including hospitals, specialty clinics, ambulatory surgical centers, and others.

Tariffs are influencing the peyronies disease treatment market by increasing the cost of imported medical devices, injectable therapies, and surgical instruments required for both non-surgical and surgical interventions. This is raising overall treatment costs and limiting accessibility, particularly in regions dependent on imported urology devices such as Asia-Pacific and parts of Latin America. Device-based and surgical segments are most affected due to high reliance on precision-engineered foreign equipment and components. However, tariffs are also encouraging localized manufacturing of medical devices, strengthening regional supply chains, and driving investment in domestic urology treatment ecosystems, which may improve long-term affordability and availability.

The peyronies disease treatment market size has grown rapidly in recent years. It will grow from $1.05 billion in 2025 to $1.16 billion in 2026 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to rising prevalence of Peyronie's disease and associated erectile dysfunction cases, increasing awareness of male sexual health disorders, limited early-stage non-surgical treatment options availability, growing adoption of surgical correction procedures in severe cases, expansion of urology specialty care infrastructure.

The peyronies disease treatment market size is expected to see rapidly grown in the next few years. It will grow to $1.73 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to increasing development of novel antifibrotic drug therapies and biologics, rising demand for non-invasive and outpatient treatment options, growing clinical research into regenerative medicine approaches for penile tissue repair, increasing patient preference for combination therapy protocols, expanding healthcare access and reimbursement support for men's health treatments. Major trends in the forecast period include oral pharmacological therapy expansion, rising adoption of collagenase injection-based treatments for plaque reduction, increasing preference for penile traction device therapy in curvature correction, growing utilization of low-intensity shockwave therapy for pain and fibrosis management, expanding shift toward minimally invasive surgical correction and combination therapy approaches.

The rising focus on men's health is expected to propel the growth of the peyronies disease treatment market going forward. Men's health refers to the physical, mental, and reproductive well-being of males and the prevention, diagnosis, and treatment of conditions that specifically or predominantly affect them. The focus on men's health is growing due to increasing awareness of male-specific diseases as more people and healthcare systems are recognizing conditions that uniquely affect men, leading to earlier diagnosis, better education, and improved access to targeted medical care. Focus on men's health drives peyronie's disease treatment by encouraging greater awareness, earlier diagnosis, and increasing willingness among men to seek medical consultation for urological conditions, which ultimately leads to higher adoption of specialized therapies and improved treatment outcomes. For instance, in July 2025, according to the Local Government Association, a UK-based organization, more than 2.74 million individuals accessed sexual health clinics in England in 2023, with men representing over 60% of all new sexually transmitted infection (STI) diagnoses in the country. Therefore, the rising focus on men's health is driving the growth of the peyronies disease treatment market.

Leading companies operating in the peyronies disease treatment market are focusing on developing innovative solutions, such as mixed reality injection training platforms, to enhance physician training, improve injection accuracy, and support safer and more effective treatment outcomes. Mixed reality injection training platforms are immersive medical training systems that combine virtual 3D anatomy with real-world interaction to simulate injection procedures, helping clinicians practice techniques in a risk-free environment to improve accuracy, confidence, and patient safety during actual treatments. for example, in April 2025, Endo Pharmaceuticals, a US-based pharmaceutical company, launched Endo's Spatial Computing Injection Simulator for Peyronie's disease, an innovative training solution. The product integrates immersive spatial computing environments, anatomically accurate 3D modeling, and guided procedural workflows to simulate intralesional injection techniques used in clinical management of Peyronie's disease. It enables healthcare professionals to rehearse patient-specific injection scenarios, improves understanding of plaque localization and curvature correction strategies, and reduces variability in real-world procedures through repetitive, risk-free practice. The simulator also supports standardized medical training across institutions, helping expand access to advanced Peyronie's disease therapies by improving clinician proficiency and procedural consistency.

In July 2025, Mallinckrodt plc, an Ireland-based pharmaceutical company, acquired Endo Inc. for $6.7 billion. Through this acquisition, Mallinckrodt and Endo aim to integrate complementary branded and generic portfolios, strengthening their capacity to deliver patient-centered therapies and expand access to essential medicines, while also improving supply chain efficiency and enhancing global market reach to better serve patients across high-need therapeutic areas. Endo Inc. is a US-based pharmaceutical company specializing in providing treatment for Peyronie's disease.

Major companies operating in the peyronies disease treatment market are Keenova Therapeutics plc; Coloplast A/S; Boston Scientific Corporation; Viatris Inc.

North America was the largest region in the peyronies disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peyronies disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the peyronies disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peyronie's disease treatment market consists of revenues earned by entities by providing services such as diagnostic evaluation, drug therapy, injectable treatments, shockwave therapy, surgical correction procedures, rehabilitation therapy, and patient consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The peyronie's disease treatment market also includes sales of oral medications, injectable biologics, traction devices, vacuum therapy devices, surgical instruments, and related therapeutic equipment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The peyronies disease treatment market research report is one of a series of new reports from The Business Research Company that provides peyronies disease treatment market statistics, including peyronies disease treatment industry global market size, regional shares, competitors with a peyronies disease treatment market share, detailed peyronies disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the peyronies disease treatment industry. This peyronies disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Peyronies Disease Treatment Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses peyronies disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peyronies disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The peyronies disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Treatment Type: Non Surgical Treatments; Surgical Treatments
• 2) By Route Of Administration: Oral; Injectable; Topical; Device Based Or External
• 3) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Non Surgical Treatments: Oral Drug Therapy Treatments; Intralesional Injection Therapy Treatments; Shockwave Therapy Treatments; Traction Device Therapy Treatments
• 2) By Surgical Treatments: Plication Surgery Treatments; Grafting Surgery Treatments; Penile Prosthesis Implant Surgery Treatments; Plaque Incision And Excision Surgery Treatments
• Companies Mentioned: Keenova Therapeutics plc; Coloplast A/S; Boston Scientific Corporation; Viatris Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.